
    
      Safety/Primary Outcome Parameters:

        -  Incidence, nature and severity of adverse events

        -  Incidence, nature and severity of clinical laboratory test abnormalities

      Efficacy/Secondary Outcome Parameters:

        -  Clinical remission defined as an endoscopy score of ≤ 1, a rectal bleeding score of 0,
           and an improvement or no change from baseline in the stool frequency score at the end of
           2 weeks of treatment / withdrawal visit;

        -  Clinical response rate defined as the percentage of patients with a drop of ≥3 points
           from the baseline overall modified Mayo score;

        -  Patient defined response and remission rates;

        -  Change from baseline in the overall modified Mayo score (Disease Activity Index);

        -  Change from baseline in each of the 4 individual sub-scores of the modified Mayo score;

        -  Change from baseline in Investigator Assessment of UC Symptom Score (total and
           individual symptom scores)

        -  Change from baseline in IBDQ score (total and the 4 individual dimension scores)

        -  Proportion of patients with treatment failure;

        -  Change from baseline in serum lutein levels;

        -  Change from baseline in C-reactive protein (CRP), high sensitivity CRP (hs-CRP),
           erythrocyte sedimentation rate (ESR), fecal calprotectin (FCP), and fecal lactoferrin
           (FL).

        -  Change from baseline in exploratory biomarkers including: serum interleukin-2 (IL-2),
           IL-6, IL-8, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-α),
           transforming growth factor-beta (TGF-beta), IL-4, IL-10, IL-17, IL-23, human
           beta-Defensin-2 (hBD-2), malondialdehyde (MDA), lipoxin A4 (LXA4), glutathione (GSH),
           M30 and M65 apoptosomes in serum and biopsies, and plasma and urinary isoprostane
           levels.
    
  